Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brown, P.
Right arrow Articles by Rothwell, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, P.
Right arrow Articles by Rothwell, J. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol 120, Issue 3 401-408, Copyright © 1997 by Oxford University Press

ARTICLES

Does parkinsonian action tremor contribute to muscle weakness in Parkinson's disease?

P Brown, DM Corcos and JC Rothwell
MRC Human Movement and Balance Unit, Institute of Neurology, London, UK.

The aim of this study was to see whether action tremor contributes to the weakness which can be measured in some muscles in patients with Parkinson's disease, by preventing fully fused contraction of motor units. Strength and action tremor were recorded during maximal wrist extension in patients when they were on and off antiparkinsonian medication, and in age- and sex-matched healthy subjects. Peak torque and mean rectified EMG levels were reduced by 25% and 30% (n = 7), respectively, when patients were off medication (compared with when they were on medication). In parkinsonian patients off treatment, action tremor was visible in torque and EMG records, and had a frequency of approximately 10 Hz. The absolute amplitude of this tremor was considerably smaller in patients on medication and in control subjects. In patients, medication reduced action tremor in torque and EMG by 37% and 57%, respectively, so that tremor amplitude approached that in normals. Similar changes were seen when action tremor was expressed as % peak torque of % mean rectified EMG. In parkinsonian patients off medication, a 10-Hz synchronizing influence dominates muscle activity at the wrist. The results is an incompletely fused muscle contraction, which is an important factor contributing to the weakness present in the off-medication state. Antiparkinsonian medication releases motor units from the 10-Hz synchronizing influence, enabling higher discharge rates, fused contraction and improved force generation.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
M. M. Sturman, D. E. Vaillancourt, L. V. Metman, R. A. E. Bakay, and D. M. Corcos
Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease
Brain, September 1, 2004; 127(9): 2131 - 2143.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
D. E. Vaillancourt, J. Prodoehl, L. Verhagen Metman, R. A. Bakay, and D. M. Corcos
Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson's disease
Brain, March 1, 2004; 127(3): 491 - 504.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
J. J. Sosnoff, D. E. Vaillancourt, and K. M. Newell
Aging and Rhythmical Force Output: Loss of Adaptive Control of Multiple Neural Oscillators
J Neurophysiol, January 1, 2004; 91(1): 172 - 181.
[Abstract] [Full Text]

Home page
 BrainHome page
R. Wenzelburger, B.-R. Zhang, S. Pohle, S. Klebe, D. Lorenz, J. Herzog, H. Wilms, G. Deuschl, and P. Krack
Force overflow and levodopa-induced dyskinesias in Parkinson's disease
Brain, April 1, 2002; 125(4): 871 - 879.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
S. Salenius, S. Avikainen, S. Kaakkola, R. Hari, and P. Brown
Defective cortical drive to muscle in Parkinson's disease and its improvement with levodopa
Brain, March 1, 2002; 125(3): 491 - 500.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
A. Berardelli, J. C. Rothwell, P. D. Thompson, and M. Hallett
Pathophysiology of bradykinesia in Parkinson's disease
Brain, November 1, 2001; 124(11): 2131 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J H McAuley, D M Corcos, J C Rothwell, N P Quinn, and C D Marsden
Levodopa reversible loss of the Piper frequency oscillation component in Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, April 1, 2001; 70(4): 471 - 475.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. H. McAuley and C. D. Marsden
Physiological and pathological tremors and rhythmic central motor control
Brain, August 1, 2000; 123(8): 1545 - 1567.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. A. Burnett, D. H. Laidlaw, and R. M. Enoka
Coactivation of the antagonist muscle does not covary with steadiness in old adults
J Appl Physiol, July 1, 2000; 89(1): 61 - 71.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J. Jankovic, K. S Schwartz, and W. Ondo
Re-emergent tremor of Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, November 1, 1999; 67(5): 646 - 650.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.